Previous
RB Leipzig
Hertha Berlin
9:30 AM UTC
Game Details
FC Augsburg
SC Paderborn 07
11:30 AM UTC
Game Details
FC Union Berlin
Mainz
11:30 AM UTC
Game Details
Fortuna Düsseldorf
Schalke 04
11:30 AM UTC
Game Details
TSG Hoffenheim
FC Cologne
11:30 AM UTC
Game Details
Next

Sources: Barca approach Zagreb for Olmo

Transfers
Read
Dinamo ZagrebDinamo Zagreb
Manchester CityManchester City
1
4
FT
Game Details
AtalantaAtalanta
Dinamo ZagrebDinamo Zagreb
2
0
FT
Game Details
Dinamo ZagrebDinamo Zagreb
Shakhtar DonetskShakhtar Donetsk
3
3
FT
Game Details
Shakhtar DonetskShakhtar Donetsk
Dinamo ZagrebDinamo Zagreb
2
2
FT
Game Details
Manchester CityManchester City
Dinamo ZagrebDinamo Zagreb
2
0
FT
Game Details
Dinamo ZagrebDinamo Zagreb
AtalantaAtalanta
4
0
FT
Game Details

Dinamo Zagreb's Arijan Ademi at CAS to fight four-year ban for doping

Arijan Ademi tested positive following a game against Arsenal in 2015.

LAUSANNE, Switzerland -- Dinamo Zagreb midfielder Arijan Ademi has testified at the Court of Arbitration for Sport to fight his four-year ban for doping in the Champions League.

CAS says Ademi appeared in person on Friday to appeal against UEFA, which judged it a serious first offense. A verdict is expected within weeks.

Ademi tested positive for the anabolic steroid stanozolol after Dinamo's 2-1 win over Arsenal in September 2015.

In his UEFA appeal case, the 25-year-old Macedonia midfielder blamed a contaminated batch of a supplement called Megamin.

UEFA dismissed the player's evidence that food testing laboratories in the Netherlands and United States found steroid traces in supplement tablets.

UEFA called that evidence "absolutely invalid" because the labs received tablets "in unsealed and even damaged containers, which clearly subjected them to external manipulation."

Comments

Use a Facebook account to add a comment, subject to Facebook's Terms of Service and Privacy Policy. Your Facebook name, photo & other personal information you make public on Facebook will appear with your comment, and may be used on ESPN's media platforms. Learn more.